International Workshop on HIV & Pediatrics 2016

Global HIV Clinical Forum 2016

Basic Science of Integrase Inhibitors - Mark Wainberg, MD

Global HIV Clinical Forum 2016

Clinical Case Discussion 1 - Pedro Cahn, MD, PhD

Global HIV Clinical Forum 2016

Resistance Characteristics of Integrase inhibitors - Charles Boucher, MD, PhD

Global HIV Clinical Forum 2016

Integrating Science Into The Clinic: Current and Future Use of Integrase Inhibitors - Anton Pozniak, MD, FRCP

Global HIV Clinical Forum 2016

Only the Best in Botswana - Optimizing the ART Response - Ava Avalos, MD

Global HIV Clinical Forum 2016

Optimizing HIV Therapy in Resource Limited Settings - François Venter, MD, FCP, PhD

Global HIV Clinical Forum 2016

Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection - Juan Ambrosioni

Global HIV Clinical Forum 2016

Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review - George Rutherford, MD, AM

Global HIV Clinical Forum 2016

Response to Raltegravir based third-line antiretroviral therapy among Ugandan children: A Case series from an urban HIV clinic - Victor Musiime, MBChB, MMED, PhD

Global HIV Clinical Forum 2016

Cross-resistance to integrase strand transfer inhibitors (INSTIs) in 23 multiexperienced Mexican patients failing to raltegravir - Aurelio Orta-Reséndiz, MD, MSc

Global HIV Clinical Forum 2016

Pharmacological Considerations & Clinical Case Discussion - Anna Maria Geretti, MD, PhD, FRCPath

Global HIV Clinical Forum 2016

Future Challenges of HIV treatment - Stefano Vella, MD

Global HIV Clinical Forum 2016

HIV Therapy in Populations with Unique Challenges – Pediatrics - Victor Musiime, MBChB, MMED, PhD

Global HIV Clinical Forum 2016

Sensitive Detection of Tenofovir-induced Tubular Injury with Urinary ß-2 Microglobuline in Vietnam | Daisuke Mizushima

APACC 2016

Tenofovir-induced kidney tubular dysfunction in HIV-infected patients in Hong Kong | Denise Chan

APACC 2016

Using the HVTN model to conduct HIV vaccine clinical trials | Xia Jin, MD, PhD

APACC 2016

Safety and efficacy of tenofovir disoproxil fumarate plus emtricitabine for HIV pre-exposure prophylaxis in Thailand | Donn Colby, MD, MPH

APACC 2016

Hepatitis C | Ching-lung Lai, MD, FRCP, FRACP

APACC 2016

Hepatitis - HIV Co-infection | Jürgen Rockstroh, MD

APACC 2016

Long Acting Antivirals for Treatment and Prevention | Martin Markowitz, MD

APACC 2016

Innovative Clinical Models | Nittaya Phanuphak, MD, PhD

APACC 2016

Towards an HIV Cure; clinical strategies and trials | Jintanat Ananworanich, MD, PhD

APACC 2016